RxDoctor Payments Data

Jayaprakash Sreenarasimhaiah, MD

Gastroenterology · Irving, TXNPI 1053378448

Payments from drug & device makers

$70,746in general payments, 2019–2025

Across 282 payments — averaging $250.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$69K
  • Takeda Pharmaceuticals U.S.A., Inc.$215
  • Johnson & Johnson$205
  • Boston Scientific$165
  • Intercept Pharmaceuticals, Inc.$161
  • Bristol Myers Squibb$116
  • plus $1K from 27 others

What the payments were for

  • Consulting fees$500%
  • Speaking & faculty fees$63,25089%
  • Travel & lodging$1,4362%
  • Food & beverage$5,9268%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,746 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$99,999
Medicare patients
347
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase23$70,561
LinzessLinaclotide27$28,372
ClenpiqSod Picosulf/Mag Ox/Citric Ac108$18,093
Mesalamine19$6,384
Dexlansoprazole DrDexlansoprazole17$4,046
Esomeprazole Magnesium39$3,243
Famotidine135$2,422
Omeprazole158$2,238
Pantoprazole Sodium221$2,147
Dicyclomine Hcl86$1,448
CholestyramineCholestyramine (With Sugar)17$1,151
Lubiprostone20$900
Lactulose18$777
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates11$718
Colestipol Hcl12$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$68,550$98,93350 claims
Ferring Pharmaceuticals Inc.Clenpiq$24$18,093108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →